Particular attention is paid to statins, such as simvastatin, atorvastatin, rosuvastatin.The article describes how these parameters should be taken into account by a practitioner.Side effects of these preparations and the possibility of their interaction with other pharmaceutical products are considered to prevent side effects, serious side effects and the lack of effectiveness of statins.The main focus is on statins, since they are considered the most prescribed, highly effective and safe preparations for the secondary cardiovascular prophylaxis.However, increasing levels of consumption of these drugs and new data on their adverse reactions leave issues of monitoring adverse drug reactions relevant not only in the field of clinical research and testing, but also in the work of a practitioner.Currently, lipidlowering therapy with statins is considered as a longterm strategy for the secondary prevention of cardiovascular diseases and severe ischemic outcomes: death, apoplectic attack, myocardial infarction.This class of drugs has confirmed a strong effect on reducing mortality from cardiovascular complications with good tolerance and high safety of these drugs.When deciding on the necessity for therapy and the nature of its regimen, target lipoprotein levels in accordance with current recommendations, the risks and benefits ratio for a particular patient should also be considered.When prescribing generic drugs, the same degree of effectiveness and safety is guaranteed only in the case of proven therapeutic equivalence to the original drug.Therefore, the practitioner has the problem of choosing the drug and personalizing pharmacotherapy.It is undoubted that the selection algorithm should be as objective as possible and take into account the following selection criteria: efficiency, evidence base, safety and cost.The purpose of the study was to assess the clinical safety of the use of statins in secondary prevention of CVD.A decrease in the intracellular concentration of cholesterol causes the expression of LDL receptors on the surface of hepatocytes, which contributes to an increase in the extraction of LDLC from the blood and a decrease in the concentration of circulating LDLC and other lipoproteins containing apoprotein B.The efficacy of statins on mortality in general, apoplectic attack rates, renal function, and side effects remain uncertain.The patients taking statins needed dialysis no less than other patients.A higher mortality rate in the hospital was not observed in them, and the incidence of adverse events was not increased.Statins had a good effect on the cardiovascular complications morbidity rate, mainly due to a general decrease in coronary syndromes. Statins were the only drugs for which consistent, clear evidence of a positive effect on all cardiovascular events, all coronary events, and stroke was obtained.A dose of mg should be considered only in patients with severe hypercholesterinemia and a high risk of cardiovascular complications who did not achieve their treatment goals with small doses, when the expected benefit exceeds the potential risks.According to the guidelines, the following statins are used simvastatin, atorvastatin, rosuvastatin, proprotein convertase subtilisinkexin type evinacumab, evolocumab, inclisiran, alirocumab, bococizumab, and ezetimibe the selective cholesterol absorption inhibitor.From the above drugs, only simvastatin is available in the WHO model formulary.Inclisiran has partial approval in the EMA; bococizumab is not represented in the FDA and EMA.